Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series

Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series

Background Immune checkpoint inhibitor (ICI) gastrointestinal toxicity (gastritis, enteritis, colitis) is a major cause of morbidity and treatment-related death. Guidelines agree steroid-refractory cases warrant infliximab, however best management of infliximab-refractory ICI gastrointestinal toxici...

Full description

Bibliographic Details
Main Authors: Lisa Zimmer, Bastian Schilling, Yinghong Wang, Georgina V Long, Jennifer McQuade, Ana Arance, Douglas B Johnson, Nadia Yousaf, Kazi J Nahar, Matteo S Carlino, Kate Young, Joanna Lee, Liselotte Tas, Serigne N Lo, Christian Blank, Alexander Maxwell Menzies, Catriona Harvey, Janet McKeown, Sheima Farag, Aafke Meerveld-Eggink, Austin Thomas, Roberto Martín Huertas
Format: Article
Language:English
Published: BMJ Publishing Group 2024-01-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/12/1/e008232.full

Internet

https://jitc.bmj.com/content/12/1/e008232.full

Similar Items